Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004380|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : June 24, 2005
OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma).
II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and cultured from skin biopsies.
|Condition or disease||Intervention/treatment||Phase|
|Systemic Sclerosis||Drug: relaxin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1 participants|
|Study Start Date :||December 1991|
|Estimated Study Completion Date :||December 1997|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004380
|Study Chair:||G. Scott Herron||Stanford University|